We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+13.8%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.5B
AUM Growth
+$1.96B
Cap. Flow
+$582M
Cap. Flow %
4.02%
Top 10 Hldgs %
31.8%
Holding
146
New
31
Increased
52
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$319M
2
IMMU
Immunomedics Inc
IMMU
+$296M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$216M
4
NYT icon
New York Times
NYT
+$130M
5
HLT icon
Hilton Worldwide
HLT
+$129M

Top Sells

Rank Stock Value
1
PPLI
People Inc
PPLI
+$456M
2
WUBA
58.com Inc
WUBA
+$268M
3
CRM icon
Salesforce
CRM
+$181M
4
QGEN icon
Qiagen
QGEN
+$123M
5
CZR
Caesars Entertainment Corporation
CZR
+$97.2M

Sector Composition

Rank Sector Weight
1 Healthcare 44.6%
2 Communication Services 17.58%
3 Technology 8.94%
4 Financials 7.39%
5 Industrials 5.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVA
101
Inventiva
IVA
$1.11B
$6.23M 0.04%
+527,870
New +$6.05M
SVRA icon
102
Savara
SVRA
$1.15B
$4.85M 0.03%
4,452,086
-18,878
-0.4% -$32.3K
ARYBU
103
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$4.43M 0.03%
402,523
+2,523
+0.6% +$28.6K
ISEE
104
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.26M 0.03%
754,740
+4,740
+0.6% +$22.6K
ACIA
105
DELISTED
Acacia Communications Inc
ACIA
$4.04M 0.03%
+60,000
New +$4.07M
EQ icon
106
Equillium
EQ
$146M
$4.04M 0.03%
+700,000
New +$5.67M
DYN icon
107
Dyne Therapeutics
DYN
$4.87B
$4.04M 0.03%
+200,000
New +$4.39M
QTNT
108
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.21M 0.02%
+15,625
New +$4.05M
CRDF icon
109
Cardiff Oncology
CRDF
$68.5M
$2.84M 0.02%
+200,000
New +$1.32M
FUSN
110
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.25M 0.02%
187,600
-62,400
-25% -$853K
BRMK.WS
111
DELISTED
Broadmark Realty Capital Inc. Warrants, each exercisable for one fourth (1/4th) share of Common Stock at an exercise price of $2.875 per quarter share
BRMK.WS
$2.06M 0.01%
7,174,613
– –
AMWL icon
112
American Well
AMWL
$202M
$1.33M 0.01%
+2,250
New +$1.19M
PAND
113
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$1.15M 0.01%
+100,000
New +$1.71M
GOL
114
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
$524K ﹤0.01%
85,838
– –
AKBA icon
115
Akebia Therapeutics
AKBA
$251M
– –
-750,000
Closed -$10.2M
AMRN
116
Amarin Corp
AMRN
$298M
– –
-156,250
Closed -$21.6M
CRSP icon
117
CRISPR Therapeutics
CRSP
$5.75B
– –
-150,000
Closed -$11M
CTMX icon
118
CytomX Therapeutics
CTMX
$715M
– –
-148,952
Closed -$1.24M
FXI icon
119
PUT
iShares China Large-Cap ETF
FXI
$4.28B
– –
-562,500
Closed -$22.3M
GOSS icon
120
Gossamer Bio
GOSS
$75.6M
– –
-100,000
Closed -$1.3M
PPLI
121
People Inc
PPLI
$2.86B
– –
-7,889,525
Closed -$456M
KPTI icon
122
Karyopharm Therapeutics
KPTI
$44.5M
– –
-89,000
Closed -$25.3M
QGEN icon
123
Qiagen
QGEN
$9.1B
– –
-2,716,943
Closed -$123M
RNAM
124
DELISTED
Avidity Biosciences
RNAM
– –
-50,000
Closed -$1.41M
RPRX icon
125
Royalty Pharma
RPRX
$27.3B
– –
-275,000
Closed -$13.4M
2 3 4
5
6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2020 Portfolio in Review

As of Q3 2020, Thomas Steyer held 146 positions worth $14.5B, up 16% from $12.5B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Thomas Steyer deployed $582M of net new capital in Q3 2020, opening 31 new positions and adding to 52 existing holdings. Its largest new stake was Boston Scientific: 8,275,919 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 43% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Salesforce, an estimated $181M trimmed.

  • Thomas Steyer's largest Q3 2020 buy was Boston Scientific: 8,275,919 shares worth $316M.
  • Thomas Steyer added most to Alphabet (Google) Class C in Q3 2020, an estimated $216M increase.
  • Thomas Steyer's biggest Q3 2020 reduction was Salesforce, cutting an estimated $181M.
  • Thomas Steyer fully exited People Inc in Q3 2020, selling an estimated $456M.
  • Thomas Steyer's ten largest holdings make up 32% of its $14.5B portfolio in Q3 2020.
  • Thomas Steyer opened 31 new positions and closed 24 in Q3 2020.
  • Thomas Steyer's portfolio value rose 16% quarter-over-quarter to $14.5B.

Based on Farallon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.